JP2017530171A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530171A5 JP2017530171A5 JP2017518340A JP2017518340A JP2017530171A5 JP 2017530171 A5 JP2017530171 A5 JP 2017530171A5 JP 2017518340 A JP2017518340 A JP 2017518340A JP 2017518340 A JP2017518340 A JP 2017518340A JP 2017530171 A5 JP2017530171 A5 JP 2017530171A5
- Authority
- JP
- Japan
- Prior art keywords
- carcinoma
- pharmaceutical composition
- composition according
- compound
- epithelial tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 201000008275 breast carcinoma Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 201000001514 prostate carcinoma Diseases 0.000 claims 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 3
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 2
- 102000003676 Glucocorticoid Receptors Human genes 0.000 claims 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000018554 digestive system carcinoma Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 229940123037 Glucocorticoid antagonist Drugs 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010054949 Metaplasia Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 201000005179 adrenal carcinoma Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 1
- 229960004671 enzalutamide Drugs 0.000 claims 1
- 239000003635 glucocorticoid antagonist Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000015689 metaplastic ossification Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000012991 uterine carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14188063.3 | 2014-10-08 | ||
| EP14188063.3A EP3006453A1 (en) | 2014-10-08 | 2014-10-08 | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
| PCT/EP2015/073172 WO2016055533A1 (en) | 2014-10-08 | 2015-10-07 | 17a,21-diesters of cortexolone for use in the treatment of tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019006199A Division JP7028809B2 (ja) | 2014-10-08 | 2019-01-17 | コルテキソロン１７α－バレレートを含む腫瘍治療に用いるための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530171A JP2017530171A (ja) | 2017-10-12 |
| JP2017530171A5 true JP2017530171A5 (enExample) | 2018-11-15 |
| JP6503057B2 JP6503057B2 (ja) | 2019-04-17 |
Family
ID=51687868
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518340A Active JP6503057B2 (ja) | 2014-10-08 | 2015-10-07 | 腫瘍治療に用いるためのコルテキソロンの１７α，２１−ジエステル |
| JP2017518978A Active JP6735739B2 (ja) | 2014-10-08 | 2015-10-07 | 腫瘍治療に用いるためのコルテキソロンの１７α−ベンゾエート |
| JP2019006199A Active JP7028809B2 (ja) | 2014-10-08 | 2019-01-17 | コルテキソロン１７α－バレレートを含む腫瘍治療に用いるための組成物 |
| JP2020092411A Pending JP2020143140A (ja) | 2014-10-08 | 2020-05-27 | 腫瘍治療に用いるためのコルテキソロンの１７α−ベンゾエート |
| JP2020199555A Pending JP2021046418A (ja) | 2014-10-08 | 2020-12-01 | コルテキソロン１７α−バレレートを含む腫瘍治療に用いるための組成物 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518978A Active JP6735739B2 (ja) | 2014-10-08 | 2015-10-07 | 腫瘍治療に用いるためのコルテキソロンの１７α−ベンゾエート |
| JP2019006199A Active JP7028809B2 (ja) | 2014-10-08 | 2019-01-17 | コルテキソロン１７α－バレレートを含む腫瘍治療に用いるための組成物 |
| JP2020092411A Pending JP2020143140A (ja) | 2014-10-08 | 2020-05-27 | 腫瘍治療に用いるためのコルテキソロンの１７α−ベンゾエート |
| JP2020199555A Pending JP2021046418A (ja) | 2014-10-08 | 2020-12-01 | コルテキソロン１７α−バレレートを含む腫瘍治療に用いるための組成物 |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US10183030B2 (enExample) |
| EP (4) | EP3006453A1 (enExample) |
| JP (5) | JP6503057B2 (enExample) |
| KR (5) | KR102520411B1 (enExample) |
| CN (5) | CN111285913B (enExample) |
| AU (3) | AU2015329999B2 (enExample) |
| BR (2) | BR112017007078A2 (enExample) |
| CA (3) | CA2962746A1 (enExample) |
| DK (2) | DK3456330T3 (enExample) |
| ES (3) | ES2806094T3 (enExample) |
| HR (2) | HRP20190194T1 (enExample) |
| HU (2) | HUE055143T2 (enExample) |
| IL (3) | IL272095B2 (enExample) |
| LT (2) | LT3204400T (enExample) |
| MX (3) | MX366294B (enExample) |
| PL (2) | PL3204400T3 (enExample) |
| PT (2) | PT3204400T (enExample) |
| RS (2) | RS62147B1 (enExample) |
| RU (2) | RU2712950C2 (enExample) |
| SI (2) | SI3204400T1 (enExample) |
| TR (1) | TR201901422T4 (enExample) |
| WO (2) | WO2016055537A1 (enExample) |
| ZA (2) | ZA201702209B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| US10413540B2 (en) | 2017-03-31 | 2019-09-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN117281790A (zh) | 2018-12-19 | 2023-12-26 | 科塞普特治疗公司 | 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂 |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN110698527B (zh) * | 2019-11-19 | 2022-08-26 | 湖南新合新生物医药有限公司 | 一种高纯度氢化可的松-17-戊酸酯的制备方法 |
| CN112028956A (zh) * | 2020-09-10 | 2020-12-04 | 那路新 | 合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法 |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN114113603B (zh) * | 2021-06-30 | 2023-11-17 | 四川大学华西医院 | Cytl1作为胃癌预后标志物的应用 |
| WO2023088308A1 (zh) * | 2021-11-16 | 2023-05-25 | 石家庄迪斯凯威医药科技有限公司 | 一种具有抗耐药性的抗菌化合物 |
| KR20250073629A (ko) | 2022-10-06 | 2025-05-27 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 글루코코르티코이드 수용체 조절제의 제형 |
| EP4608402A1 (en) | 2022-10-28 | 2025-09-03 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE619180A (fr) * | 1961-06-24 | 1962-12-20 | Vismara Francesco Spa | 17-monoesters de 17 alpha, 21-dihydroxy stéroïdes et leur procédé de préparation |
| DE1195748B (de) * | 1961-06-24 | 1965-07-01 | Vismara Francesco Spa | Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden |
| NL6605514A (enExample) | 1966-04-25 | 1967-10-26 | ||
| DE2748442C3 (de) | 1977-10-26 | 1981-08-27 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | 17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel |
| EP0001737B1 (de) * | 1977-10-26 | 1981-01-07 | Schering Aktiengesellschaft | 17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung |
| ATE12237T1 (de) * | 1980-12-23 | 1985-04-15 | Schering Ag | Neue 6-alpha-methylhydrocortison-derivate, ihre herstellung und verwendung. |
| ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| US4920216A (en) * | 1987-05-28 | 1990-04-24 | The Trustees Of Columbia In The City Of New York | Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates |
| US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
| WO1990009394A2 (en) | 1989-02-07 | 1990-08-23 | The Upjohn Company | Dehalogenation of organic compounds using tin or lead |
| DE4121484A1 (de) | 1991-06-26 | 1993-01-07 | Schering Ag | Verfahren zur herstellung von 6-methylensteroiden |
| US6172054B1 (en) | 1995-06-15 | 2001-01-09 | Alcon Laboratories, Inc. | Combination therapy for lowering and controlling intraocular pressure |
| WO2000049993A2 (en) | 1999-02-24 | 2000-08-31 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
| WO2000076478A1 (en) | 1999-06-14 | 2000-12-21 | Cosmo S.P.A. | Controlled release and taste masking oral pharmaceutical compositions |
| IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
| AU1770901A (en) | 2000-11-16 | 2002-05-27 | Alcon Lab Inc | Combination therapy for lowering and controlling intraocular pressure |
| ITMI20011762A1 (it) * | 2001-08-10 | 2003-02-10 | Cosmo Spa | Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione |
| ITMI20051695A1 (it) * | 2005-09-14 | 2007-03-15 | Cosmo Spa | Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici |
| DE102006059063A1 (de) | 2005-12-24 | 2007-06-28 | Bayer Healthcare Ag | Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074 |
| US7687484B2 (en) | 2006-05-25 | 2010-03-30 | Bodor Nicholas S | Transporter enhanced corticosteroid activity |
| ITMI20071616A1 (it) * | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
| CN101397317A (zh) | 2007-09-27 | 2009-04-01 | 天津药业研究院有限公司 | 一种新型硝酸酯类甾体化合物 |
| EP2231147A2 (en) * | 2007-12-13 | 2010-09-29 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| JP2010515777A (ja) | 2008-03-18 | 2010-05-13 | シコール インコーポレイティド | 空気感受性ステロイドの精製 |
| CA2800023A1 (en) * | 2010-06-01 | 2011-12-08 | Metanomics Health Gmbh | Means and methods for diagnosing pancreatic cancer in a subject |
| EP2701744A4 (en) * | 2011-03-23 | 2014-08-20 | Pop Test Cortisol Llc | COMBINATION THERAPY |
| RU2506974C1 (ru) | 2012-11-06 | 2014-02-20 | Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации | Способ лечения первично нерезектабельного рака легкого |
| CA3105575A1 (en) | 2013-01-15 | 2014-07-24 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator and uses thereof |
| EP3006453A1 (en) | 2014-10-08 | 2016-04-13 | Cosmo Technologies Ltd. | 17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors |
-
2014
- 2014-10-08 EP EP14188063.3A patent/EP3006453A1/en not_active Withdrawn
-
2015
- 2015-10-07 BR BR112017007078A patent/BR112017007078A2/pt not_active Application Discontinuation
- 2015-10-07 SI SI201530614T patent/SI3204400T1/sl unknown
- 2015-10-07 HU HUE18198653A patent/HUE055143T2/hu unknown
- 2015-10-07 KR KR1020217002286A patent/KR102520411B1/ko active Active
- 2015-10-07 ES ES15775455T patent/ES2806094T3/es active Active
- 2015-10-07 EP EP18198653.0A patent/EP3456330B1/en active Active
- 2015-10-07 KR KR1020177011239A patent/KR20170063821A/ko not_active Withdrawn
- 2015-10-07 PL PL15778634T patent/PL3204400T3/pl unknown
- 2015-10-07 CA CA2962746A patent/CA2962746A1/en not_active Abandoned
- 2015-10-07 HR HRP20190194TT patent/HRP20190194T1/hr unknown
- 2015-10-07 WO PCT/EP2015/073176 patent/WO2016055537A1/en not_active Ceased
- 2015-10-07 WO PCT/EP2015/073172 patent/WO2016055533A1/en not_active Ceased
- 2015-10-07 MX MX2017004660A patent/MX366294B/es active IP Right Grant
- 2015-10-07 LT LTEP15778634.4T patent/LT3204400T/lt unknown
- 2015-10-07 CN CN202010134553.1A patent/CN111285913B/zh active Active
- 2015-10-07 DK DK18198653.0T patent/DK3456330T3/da active
- 2015-10-07 MX MX2019008063A patent/MX385557B/es unknown
- 2015-10-07 KR KR1020247032041A patent/KR20240149968A/ko active Pending
- 2015-10-07 US US15/517,653 patent/US10183030B2/en active Active
- 2015-10-07 RU RU2017115771A patent/RU2712950C2/ru active
- 2015-10-07 AU AU2015329999A patent/AU2015329999B2/en active Active
- 2015-10-07 HU HUE15778634A patent/HUE041503T2/hu unknown
- 2015-10-07 CN CN202211425819.3A patent/CN115671114A/zh active Pending
- 2015-10-07 TR TR2019/01422T patent/TR201901422T4/tr unknown
- 2015-10-07 CN CN202211571443.7A patent/CN116102604A/zh active Pending
- 2015-10-07 ES ES15778634T patent/ES2713699T3/es active Active
- 2015-10-07 EP EP15778634.4A patent/EP3204400B1/en active Active
- 2015-10-07 BR BR112017007076-6A patent/BR112017007076B1/pt active IP Right Grant
- 2015-10-07 CA CA3160391A patent/CA3160391C/en active Active
- 2015-10-07 PL PL18198653T patent/PL3456330T3/pl unknown
- 2015-10-07 US US15/517,659 patent/US10231980B2/en active Active
- 2015-10-07 KR KR1020177011114A patent/KR102248983B1/ko active Active
- 2015-10-07 KR KR1020237011743A patent/KR102712584B1/ko active Active
- 2015-10-07 RS RS20210928A patent/RS62147B1/sr unknown
- 2015-10-07 LT LTEP18198653.0T patent/LT3456330T/lt unknown
- 2015-10-07 JP JP2017518340A patent/JP6503057B2/ja active Active
- 2015-10-07 RS RS20190207A patent/RS58607B1/sr unknown
- 2015-10-07 MX MX2017004661A patent/MX2017004661A/es unknown
- 2015-10-07 RU RU2017115773A patent/RU2712752C2/ru active
- 2015-10-07 CN CN201580060690.2A patent/CN107001406B/zh active Active
- 2015-10-07 SI SI201531666T patent/SI3456330T1/sl unknown
- 2015-10-07 JP JP2017518978A patent/JP6735739B2/ja active Active
- 2015-10-07 PT PT15778634T patent/PT3204400T/pt unknown
- 2015-10-07 IL IL272095A patent/IL272095B2/en unknown
- 2015-10-07 CN CN201580060711.0A patent/CN107074905B/zh not_active Expired - Fee Related
- 2015-10-07 CA CA2960928A patent/CA2960928C/en active Active
- 2015-10-07 PT PT181986530T patent/PT3456330T/pt unknown
- 2015-10-07 ES ES18198653T patent/ES2882223T3/es active Active
- 2015-10-07 EP EP15775455.7A patent/EP3204012B1/en active Active
- 2015-10-07 DK DK15778634.4T patent/DK3204400T3/en active
- 2015-10-07 AU AU2015330003A patent/AU2015330003A1/en not_active Abandoned
-
2017
- 2017-03-08 IL IL251028A patent/IL251028B/en active IP Right Grant
- 2017-03-23 IL IL251371A patent/IL251371A0/en unknown
- 2017-03-29 ZA ZA2017/02209A patent/ZA201702209B/en unknown
-
2018
- 2018-11-23 US US16/199,015 patent/US10646497B2/en active Active
-
2019
- 2019-01-17 JP JP2019006199A patent/JP7028809B2/ja active Active
- 2019-02-12 US US16/273,575 patent/US20190175618A1/en not_active Abandoned
- 2019-04-12 ZA ZA2019/02320A patent/ZA201902320B/en unknown
-
2020
- 2020-02-27 AU AU2020201446A patent/AU2020201446B2/en active Active
- 2020-03-16 US US16/820,407 patent/US10993949B2/en active Active
- 2020-05-27 JP JP2020092411A patent/JP2020143140A/ja active Pending
- 2020-12-01 JP JP2020199555A patent/JP2021046418A/ja active Pending
-
2021
- 2021-04-06 US US17/223,776 patent/US11712443B2/en active Active
- 2021-07-22 HR HRP20211177TT patent/HRP20211177T1/hr unknown
-
2022
- 2022-12-19 US US18/068,346 patent/US11986484B2/en active Active
-
2024
- 2024-03-01 US US18/592,730 patent/US20240277731A1/en active Pending